The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers
<p>Interleukin-6 (IL-6) is one of the pro-infl ammatory cytokines involved in pathogenesis of various autoimmune and chronic infl ammatory diseases. IL-6 through binding to its cellular receptor can transduce both classical- and trans-signaling pathways. Overproduction of circulating IL-6 can...
সংরক্ষণ করুন:
প্রধান লেখক: | |
---|---|
বিন্যাস: | গ্রন্থ |
প্রকাশিত: |
Rheumatica Acta: Open Access - Peertechz Publications,
2017-03-02.
|
বিষয়গুলি: | |
অনলাইন ব্যবহার করুন: | Connect to this object online. |
ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | peertech__10_17352_raoa_000003 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Deng-Ho Yang |e author |
245 | 0 | 0 | |a The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers |
260 | |b Rheumatica Acta: Open Access - Peertechz Publications, |c 2017-03-02. | ||
520 | |a <p>Interleukin-6 (IL-6) is one of the pro-infl ammatory cytokines involved in pathogenesis of various autoimmune and chronic infl ammatory diseases. IL-6 through binding to its cellular receptor can transduce both classical- and trans-signaling pathways. Overproduction of circulating IL-6 can be detected in patients with different autoimmune diseases. Tocilizumab, a humanized monoclonal antibody against IL-6 receptor, can block IL-6-mediated signaling and has been approved for the treatment of rheumatoid arthritis and Castleman's disease. Besides, expression of IL-6 may promote tumorigenesis and has been detected in various tumors, including multiple myeloma, colorectal cancer, breast cancer, lymphoma, breast cancer and lung cancer. Furthermore, increased levels of circulating IL-6 are associated with poor prognosis and cachexia in cancer patients. Monotherapy with IL-6 blockade or a combination therapy with both IL-6 blockade and conventional chemotherapy may reduce the progression of cancer and improve the status of cachexia in cancer patients. Finally, based upon the known biological effects of IL-6, diseases, other than autoimmune diseases and cancers, potentially to be anti-IL-6 candidates will be briefl y discussed.</p> | ||
540 | |a Copyright © Deng-Ho Yang et al. | ||
546 | |a en | ||
655 | 7 | |a Review Article |2 local | |
856 | 4 | 1 | |u https://doi.org/10.17352/raoa.000003 |z Connect to this object online. |